Cash Cash Equivalents - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.1 PLN -1.64% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ryvu Therapeutics SA
Cash & Cash Equivalents Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Cash & Cash Equivalents
zł20m
CAGR 3-Years
-45%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Cash & Cash Equivalents
zł294k
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
-5%
M
Medicofarma Biotech SA
WSE:MDB
Cash & Cash Equivalents
zł507.6k
CAGR 3-Years
194%
CAGR 5-Years
8%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Cash & Cash Equivalents
zł44.3m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
20m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Cash & Cash Equivalents amounts to 20m PLN.

What is Ryvu Therapeutics SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-27%

Over the last year, the Cash & Cash Equivalents growth was 132%. The average annual Cash & Cash Equivalents growth rates for Ryvu Therapeutics SA have been -45% over the past three years , -27% over the past five years .

Back to Top